News

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...